Share

February 2021; 7 (1) EditorialOpen Access

Molecular Diagnosis in 100% of Dystrophinopathies

Are We There Yet?

Elena Pegoraro
First published January 29, 2021, DOI: https://doi.org/10.1212/NXG.0000000000000529
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
422

Share

Article Information

vol. 7 no. 1 e529
DOI: 
https://doi.org/10.1212/NXG.0000000000000529
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Online ISSN: 
2376-7839
History: 
  • First Published January 29, 2021.
Copyright & Usage: 
Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Author Disclosures

    1. Elena Pegoraro, MD, PhD
  1. Elena Pegoraro, MD, PhD
    2. Scientific Advisory Boards:

    1. PTC Pharmaceuticals, commercial entity Sarepta, commercial entity Santhera, commercial entity Genzyme, commercial entity Roche, commercial entity Biogen, commercial entity

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Received funding for travel and educational support from Genzyme. Received funding for travel support from Santhera.

    Editorial Boards:

    1. Serving as editorial advisory board member of Acta Myologica

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. Received institutional support from the University of Padova

    Research Support, Foundations and Societies:

    1. Cariparo Foundation Padova Italy, University of Padova

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the ERN Neuromuscular Unit, Department of Neurosciences, DNS, University of Padova, Padova, Italy.
  1. Correspondence
    Dr. Pegoraro elena.pegoraro{at}unipd.it
View Full Text

Article usage

Article usage: January 2021 to August 2023

AbstractFullPdfSource
Jan 20210475Highwire
Feb 2021635576Highwire
Mar 202157021Highwire
Apr 202102918Highwire
May 202122610Highwire
Jun 202134334Highwire
Jul 202113114Highwire
Aug 20211217Highwire
Sep 202112614Highwire
Oct 202102316Highwire
Nov 202101722Highwire
Dec 202111210Highwire
Jan 2022273Highwire
Feb 2022193Highwire
Mar 202201217Highwire
Apr 20220126Highwire
May 20221109Highwire
Jun 20221119Highwire
Jul 20220115Highwire
Aug 20220136Highwire
Sep 20221229Highwire
Oct 202202817Highwire
Nov 202205125Highwire
Dec 202202411Highwire
Jan 202313113Highwire
Feb 20231198Highwire
Mar 2023085Highwire
Apr 2023033Highwire
May 202303166Highwire
Jun 2023055Highwire
Jul 2023033Highwire
Aug 202301112Highwire

Cited By...

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

Topics Discussed

Alert Me

Recommended articles